Trial intelligence / Profile preview

The Moody Longevity Trial

NCT07220473Phase 2

Key facts

Status: Recruiting
Start: Feb 2026
Primary completion: Nov 2027
Countries: 1
Sponsor: The University of Texas Medical Branch at Galveston
Modality: Peptides, Recombinant Proteins and Enzymes

Drugs: tirzepatide
Conditions: aging

Overview

Phase 2, randomised, open-label trial in aging comparing Tirzepatide with Placebo (No Intervention) (2 arms). Primary endpoint: Change in DNA Methylation-Based Biological Age at 24 weeks. Started Feb 2026; status: recruiting.

Design

2 arms

Study design: RandomizedOpen-label

Tirzepatide
Participants will receive Tirzepatide 2.5 mg weekly for 24 weeks, followed by a 12-week off-drug follow-up.
Placebo (No Intervention)
Participants will be monitored for a total of 36 weeks without receiving medication.

Who it enrols

Adults aged 55-70 with a BMI between 27 and 35 kg/m^2 and an indication for weight-loss therapy, without severe cardiometabolic or neurocognitive diseases.

Endpoints

Primary

Change in DNA Methylation-Based Biological Age24 weeks

Secondary

Self-reported tolerability and acceptability24 weeks
Changes in BMI and weight36 weeks
Changes in physical function36 weeks
Changes in inflammatory, aging and neurocognitive biomarker profiles36 weeks

Beyond the preview

Go deeper on NCT07220473.

Full results, competitive context and analysis are in the Gosset platform.

Full results & analysis

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT07220473.